Hypopituitarism

  • Jan 17, 2019 www.medscape.com
    Endocrinopathy After Cancer Therapy: The Downside of Success – Medscape
    Read More
  • Jan 14, 2019 www.streetinsider.com
    Bristol-Myers Squibb (BMY) Announces European Commission Approval for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) – StreetInsider.com
    Read More
  • Jan 03, 2019 sciencetrends.com
    Explaining Why Concussions May Activate A Pituitary “Dimmer Switch” – Science Trends
    Read More
  • Carcinoma in Cushing’s Patient Treated with Radiation, Chemo, Report Says – Cushing’s Disease News
    Read More
  • Jan 03, 2019 www.streetinsider.com
    Merck (MRK) Announces Five New Approvals for KEYTRUDA (pembrolizumab) in Japan, Including 3 Expanded Uses in Advanced NSCLC – StreetInsider.com
    Read More
  • Dec 21, 2018 www.prnewswire.com
    Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer – PRNewswire
    Read More
  • Dec 20, 2018 apnews.com
    Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial – Associated Press
    Read More
  • Dec 19, 2018 www.businesswire.com
    FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer – Business Wire
    Read More
  • Dec 17, 2018 www.businesswire.com
    European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma – Business Wire
    Read More

Connect. Empower. Inspire.